Dr. Kristin Comella Joins Top Docs in Fix for Female Hormones Seminar

SUNRISE, FL – September 26, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced its Chief Science Officer, Dr. Kristin Comella, will be featured alongside other top doctors in the upcoming webinar summit, the Fix for Female Hormones.

Hosted by Misty Williams, the summit provides a platform for alternative and medical health professionals to weigh in on options for women seeking education and information about ways to create and establish optimal hormonal health.  Dr. Comella will present about understanding regenerative medicine; protecting telomeres and supporting healthy aging; ways to support hormones and restore sexual response, and heal exhaustion.

Dr. Comella’s segment will air for the first time on Oct. 6.  To learn more about the summit, which is free, click here, https://fixforfemalehormones.com/.  

“The way we define aging in America is changing, basically because we are waking up to the healing potential with our own bodies, and autologous stem cell therapy is a big part of that,” said Dr. Comella.  “The opportunity to help educate about regenerative therapy in the context of hormonal balance, with a panel of experts each bringing a unique perspective to the topic, is a perfect opportunity to learn more about natural approaches to this ongoing issue.”

Under Dr. Comella’s leadership, USRM has been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases.  

USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.  

U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead therapy Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics.  To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.